MabVax Therapeutics

Biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies.

Launch date

2006

Employees

San Diego California (HQ)

Date	Investors	Amount	Round
-	Advent International	N/A	-
Feb 2008	GBP Capital	$8.0m	Series A
Aug 2010	N/A	$1.1m	Grant
Apr 2011	N/A	$1.8m	Debt
Jan 2012	BIOMARK CAPITAL	N/A	Debt
Nov 2012	Burrill Numoda Capital Innovations	$5.3m	Series B
Sep 2013	N/A	$1.8m	Grant
Feb 2014	N/A	$12.1m	Debt
Sep 2014	N/A	N/A	IPO
Apr 2015	N/A	$11.6m	Post IPO Equity
May 2017	N/A	$4.1m	Post IPO Equity
Feb 2018*	N/A	$2.1m	Post IPO Equity
Jul 2018	Boehringer Ingelheim	$11.0m	Post IPO Equity
Nov 2018*	TRITON FUNDS	N/A	Post IPO Equity
Total Funding		$16.2m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about MabVax Therapeutics